{"result": "\n{\n    \"title\": \"PROWESS-SHOCK Study and DrotAA\",\n    \"summary\": \"The community centers around the PROWESS-SHOCK study, a clinical trial evaluating the efficacy of DrotAA in reducing mortality in patients with septic shock. Key entities include the drug DrotAA, its manufacturer Eli Lilly, and various regulatory bodies such as the FDA and the European Medicines Agency. The study's findings have significant implications for the treatment of septic shock and the approval status of DrotAA.\",\n    \"rating\": 8.5,\n    \"rating_explanation\": \"The impact severity rating is high due to the significant implications of the study's findings on the treatment of septic shock and regulatory decisions regarding DrotAA.\",\n    \"findings\": [\n        {\n            \"summary\": \"PROWESS-SHOCK study's central role\",\n            \"explanation\": \"The PROWESS-SHOCK study is a pivotal clinical trial designed to assess the efficacy of DrotAA in reducing mortality among patients with septic shock. This study is central to the community as it directly influences the approval and use of DrotAA in clinical settings. The study's outcomes have been critical in shaping the understanding of DrotAA's effectiveness, with findings indicating that DrotAA does not significantly reduce mortality in this patient population [Data: Entities (2); Relationships (1, 19, 15)].\"\n        },\n        {\n            \"summary\": \"DrotAA's regulatory challenges\",\n            \"explanation\": \"DrotAA, developed and marketed by Eli Lilly, faced significant regulatory scrutiny. The FDA limited its approval to patients with a high risk of death and requested additional trials to further assess its efficacy. Similarly, the European Medicines Agency granted marketing authorization subject to annual review. These regulatory decisions highlight the challenges faced by DrotAA in gaining widespread acceptance and underscore the importance of robust clinical evidence in the approval process [Data: Entities (4, 5); Relationships (0, 3, 4)].\"\n        },\n        {\n            \"summary\": \"Eli Lilly's involvement in DrotAA's development\",\n            \"explanation\": \"Eli Lilly played a crucial role in the development and commercialization of DrotAA. The company not only manufactured the drug but also funded the PROWESS-SHOCK study, demonstrating its vested interest in the drug's success. Eli Lilly's involvement underscores the intersection of commercial interests and clinical research, which can influence the direction and outcomes of clinical trials [Data: Relationships (0)].\"\n        },\n        {\n            \"summary\": \"Geographical scope of the PROWESS-SHOCK study\",\n            \"explanation\": \"The PROWESS-SHOCK study was conducted across multiple continents, including recruitment sites in North America, Europe, South America, Australia, New Zealand, and India. This wide geographical scope highlights the study's international reach and the diverse patient population involved, which is crucial for understanding the global applicability of the study's findings [Data: Relationships (6, 5, 7, 8, 9, 10)].\"\n        },\n        {\n            \"summary\": \"Comparison with previous studies\",\n            \"explanation\": \"The findings of the PROWESS-SHOCK study contrast with those of the earlier PROWESS study, which reported a reduction in mortality at 28 days with DrotAA. However, the current study's results are consistent with the ADDRESS and RESOLVE trials, which also showed no significant mortality benefit. These comparisons are essential for contextualizing the efficacy of DrotAA and understanding its limitations in treating severe sepsis and septic shock [Data: Entities (3, 27, 28); Relationships (16, 17, 18)].\"\n        }\n    ]\n}", "input": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\n19,AUGUST 2011,AUGUST 2011 marks the month and year when patient enrollment concluded for the study. The study successfully completed its patient enrollment phase in August 2011.,3\n23,INDIA,\"India is a country where some of the study patients were recruited for the clinical trial. It is one of the countries where the study was conducted, with centers participating in the research.\",3\n18,MARCH 2008,MARCH 2008 marks the time when patient enrollment began for the study.,3\n25,\"MAY 12, 2010\",,2\n2,PROWESS-SHOCK,The PROWESS-SHOCK study is a clinical trial conducted to evaluate the efficacy of DrotAA in reducing mortality in patients with septic shock,3\n3,PROWESS,The Prospective Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study was a phase 3 international trial that initially supported the approval of DrotAA for severe sepsis,2\n27,ADDRESS TRIAL,The ADDRESS trial is a study that showed DrotAA did not reduce mortality in patients with severe sepsis who had a low risk of death,1\n4,EUROPEAN MEDICINES AGENCY,\"The European Medicines Agency granted marketing authorization for DrotAA for the treatment of adults with severe sepsis and multiple organ failure, subject to annual review\",1\n5,FOOD AND DRUG ADMINISTRATION,The FDA limited the approval of DrotAA for use in patients with a high risk of death and requested additional trials,1\n26,PROWESS STUDY,\"The PROWESS study is a previous trial that reported a reduction in mortality at 28 days with DrotAA, which was not replicated in the current study\",1\n28,RESOLVE TRIAL,The RESOLVE trial is a study that showed DrotAA did not reduce mortality in pediatric patients with severe sepsis,1\n8,NCT00604214,,1\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\n19,DROTAA,SEPTIC SHOCK,\"DrotAA was tested as a treatment for patients with septic shock. However, studies have shown that DrotAA is ineffective as a treatment for this condition.\",91\n15,DROTAA,PLACEBO,\"DrotAA was compared to placebo in a study involving critically ill adults with septic shock, showing no significant difference in mortality\",52\n67,AUGUST 2011,PLACEBO,Patient enrollment for the placebo group ended in August 2011,34\n8,DROTAA,AUSTRALIA,Australia was a recruitment site for patients receiving DrotAA in the clinical trial,34\n89,INDIA,PLACEBO,India was a recruitment site for patients receiving placebo in the clinical trial,34\n66,MARCH 2008,PLACEBO,Patient enrollment for the placebo group began in March 2008,34\n91,PLACEBO,\"MAY 12, 2010\",\"The sample size for the placebo group was increased on May 12, 2010\",33\n9,DROTAA,NEW ZEALAND,New Zealand was a recruitment site for patients receiving DrotAA in the clinical trial,32\n14,DROTAA,APACHE II,APACHE II scores were used to assess the severity of illness in patients receiving DrotAA,32\n5,DROTAA,EUROPE,Europe was a major recruitment site for patients receiving DrotAA in the clinical trial,30\n0,DROTAA,ELI LILLY,\"Eli Lilly is the manufacturer of DrotAA, a drug that was used in the PROWESS-SHOCK study. Eli Lilly not only developed and marketed DrotAA but also funded the PROWESS-SHOCK study, demonstrating their significant involvement in both the research and commercial aspects of the drug.\",29\n6,DROTAA,NORTH AMERICA,North America was a recruitment site for patients receiving DrotAA in the clinical trial,25\n7,DROTAA,SOUTH AMERICA,South America was a recruitment site for patients receiving DrotAA in the clinical trial,25\n13,DROTAA,AUGUST 2011,Patient enrollment for the DrotAA group ended in August 2011,24\n1,DROTAA,PROWESS-SHOCK,The PROWESS-SHOCK study was conducted to test the efficacy of DrotAA in reducing mortality in septic shock patients,24\n10,DROTAA,INDIA,India was a recruitment site for patients receiving DrotAA in the clinical trial,24\n12,DROTAA,MARCH 2008,Patient enrollment for the DrotAA group began in March 2008,24\n20,DROTAA,CLINICIANS,\"Clinicians were previously using DrotAA to treat patients with septic shock, but the treatment is no longer available\",24\n2,DROTAA,PROWESS,The PROWESS study initially supported the approval of DrotAA for severe sepsis,23\n11,DROTAA,\"MAY 12, 2010\",\"The sample size for the DrotAA group was increased on May 12, 2010\",23\n17,DROTAA,ADDRESS TRIAL,\"The current study's findings are consistent with the ADDRESS trial, which showed DrotAA did not reduce mortality in patients with severe sepsis\",22\n3,DROTAA,EUROPEAN MEDICINES AGENCY,\"The European Medicines Agency granted marketing authorization for DrotAA, subject to annual review\",22\n4,DROTAA,FOOD AND DRUG ADMINISTRATION,The FDA limited the approval of DrotAA and requested additional trials,22\n16,DROTAA,PROWESS STUDY,\"The current study's findings contrast with the PROWESS study, which reported a reduction in mortality at 28 days with DrotAA\",22\n18,DROTAA,RESOLVE TRIAL,\"The current study's findings are consistent with the RESOLVE trial, which showed DrotAA did not reduce mortality in pediatric patients with severe sepsis\",22\n90,INDIA,HIGH-FREQUENCY OSCILLATORY VENTILATION (HFOV),India was one of the countries where the HFOV study was conducted,13\n30,PROWESS,APACHE II,The APACHE II score was used in the PROWESS study to identify patients with increased illness severity,13\n65,MARCH 2008,AUGUST 2011,The study enrolled patients from March 2008 to August 2011,6\n29,PROWESS-SHOCK,INSTITUTIONAL REVIEW BOARD,The Institutional Review Board approved the PROWESS-SHOCK study at each study center,6\n28,PROWESS-SHOCK,NCT00604214,NCT00604214 is the ClinicalTrials.gov number associated with the PROWESS-SHOCK study,4\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "parameters": {"model": "gpt-4o", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 2000, "n": 1}, "history": null}